62
Participants
Start Date
February 13, 2023
Primary Completion Date
February 13, 2026
Study Completion Date
February 13, 2027
Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)
Abatacept injected subcutaneously once per week and nasal insulin inhaled for 10 consecutive days initially and twice per week thereafter
Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)
Abatacept injected subcutaneously once per week and nasal placebo inhaled for 10 consecutive days initially and twice per week thereafter
The Children's Hospital at Westmead, Westmead
The Royal Melbourne Hospital, Parkville
The Royal Children's Hospital, Parkville
Queensland Children's Hospital, South Brisbane
Women's and Children's Hospital, North Adelaide
Perth Children's Hospital, Nedlands
Lead Sponsor
Collaborators (1)
National Health and Medical Research Council, Australia
OTHER
Juvenile Diabetes Research Foundation
OTHER
Melbourne Health
OTHER